{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:49:31Z","timestamp":1761396571640,"version":"build-2065373602"},"reference-count":118,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The treatment paradigms for patients with relapsed large B-cell lymphoma are expanding. Chimeric antigen receptor technology (CAR-T) has revolutionized the management of these patients. Novel bispecific antibodies and antibody\u2013drug conjugates, used as chemotherapy-free single agents or in combination with other novel therapeutics, have been quickly introduced into the real-world setting. With such a paradigm shift, patients have an improved chance of better outcomes with unpredictable complete remission rates. Additionally, the excellent tolerance of new antibodies targeting B-cell lymphomas is another motivation to broaden its use in relapsed and refractory patients. With the increasing number of approved therapy approaches, future research needs to focus on optimizing the sequence and developing new combination strategies for these antibodies, both among themselves and with other agents. Clinical, pathological, and genetic risk profiling can assist in identifying which patients are most likely to benefit from these costly therapeutic options. However, new combinations may lead to new side effects, which we must learn to deal with. This review provides a comprehensive overview of the current state of research on several innovative antibodies for the precision management of large B-cell lymphoma. It explores various treatment strategies, such as CAR-T vs. ASCT, naked antibodies, antibody\u2013drug conjugates, bispecific antibodies, and bispecific T-cell engagers, as well as discussing the challenges and future perspectives of novel treatment strategies. We also delve into resistance mechanisms and factors that may affect decision making. Moreover, each section provides a detailed analysis of the available literature and ongoing clinical trials.<\/jats:p>","DOI":"10.3390\/cells12141858","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T09:03:53Z","timestamp":1689325433000},"page":"1858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Redefining Precision Management of r\/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8221-9342","authenticated-orcid":false,"given":"Reyad","family":"Dada","sequence":"first","affiliation":[{"name":"King Faisal Specialist Hospital and Research Centre, Jeddah 21499, Saudi Arabia"},{"name":"College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"ref_1","unstructured":"Li, W. (2022). Leukemia, Exon Publications. Chapter 1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992\u20132001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/10428194.2021.1975188","article-title":"Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020\u20132025","volume":"63","author":"Kanas","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1002\/cam4.3237","article-title":"CHOP-like Chemotherapy plus Rituximab versus CHOP-like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the MabThera International Trial (MInT) Group","volume":"9","author":"Epperla","year":"2020","journal-title":"Cancer Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on Mantle Cell Lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like Chemotherapy plus Rituximab versus CHOP-like Chemotherapy Alone in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma: A Randomised Controlled Trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive Factors of Early Progression after CAR T-Cell Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3109\/10428194.2014.964702","article-title":"Lenalidomide Monotherapy in Heavily Pretreated Patients with Non-Hodgkin Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice","volume":"56","author":"Zinzani","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus Lenalidomide and Rituximab Has Promising Activity in Relapsed\/Refractory Non\u2013Germinal Center B-Cell\u2013like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A Phase II Trial of the Oral MTOR Inhibitor Everolimus in Relapsed Aggressive Lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2021-147913","article-title":"Lisocabtagene Maraleucel (Liso-Cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R\/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study","volume":"138","author":"Kamdar","year":"2021","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/10781552221110806","article-title":"Understanding the Differences in Outcome between CART Studies as Second-Line Treatment in Aggressive Lymphoma","volume":"29","author":"Dada","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"887866","DOI":"10.3389\/fimmu.2022.887866","article-title":"Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed\/Refractory DLBCL","volume":"13","author":"Jeyakumar","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.clml.2021.08.011","article-title":"Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma","volume":"22","author":"Iqbal","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.1200\/JCO.2021.39.15_suppl.7522","article-title":"Progression-Free Survival at 24 Months as a Landmark after Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"39","author":"Tun","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"TRANSFORM Investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin\u2019s Lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/hon.2975","article-title":"Chimeric Antigen Receptor T-Cell Therapy Combined with Autologous Stem Cell Transplantation Improved Progression-Free Survival of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients: A Single-Center, Retrospective, Cohort Study","volume":"40","author":"Wang","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1200\/JCO.2016.69.0198","article-title":"Ofatumumab versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study","volume":"35","author":"McMillan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large b-Cell Lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/hon.3013","article-title":"Targeting CD19 in Diffuse Large B-Cell Lymphoma: An Expert Opinion Paper","volume":"40","author":"Bailly","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bcmd.2004.03.003","article-title":"Development and Application of CD19-Specific T Cells for Adoptive Immunotherapy of B Cell Malignancies","volume":"33","author":"Cooper","year":"2004","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pytlik, R., Polgarova, K., Karolova, J., and Klener, P. (2020). Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines, 8.","DOI":"10.3390\/vaccines8040708"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-MIND): A Multicentre, Prospective, Single-Arm, Phase 2 Study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1007\/s12325-022-02094-5","article-title":"Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison","volume":"39","author":"Cordoba","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-World Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-137328","article-title":"Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression","volume":"136","author":"Smith","year":"2020","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","volume":"37","author":"Ansell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation","volume":"4","author":"Frigault","year":"2020","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"Proc. J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2021-148082","article-title":"Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)","volume":"138","author":"Zinzani","year":"2021","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1182\/blood-2022-167772","article-title":"Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"140","author":"Maakaron","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody Drug Conjugate: The \u201cBiological Missile\u201d for Targeted Cancer Therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab Vedotin or Pinatuzumab Vedotin plus Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Final Results from a Phase 2 Randomised Study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"Proc. J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab Vedotin plus Bendamustine and Rituximab in Relapsed\/ Refractory DLBCL: Survival Update and New Extension Cohort Data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab Vedotin as a Salvage and Bridging Treatment in Relapsed or Refractory Large B-Cell Lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Proc. Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/bloodadvances.2021006801","article-title":"A Multicenter Retrospective Study of Polatuzumab Vedotin in Patients with Large B-Cell Lymphoma after CAR T-Cell Therapy","volume":"6","author":"Gouni","year":"2022","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00277-022-05052-x","article-title":"Polatuzumab Vedotin, Rituximab, and Bendamustine Combination in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Real-World Data from Turkey","volume":"102","author":"Dal","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.21037\/atm-22-4593","article-title":"A Retrospective Cohort Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Chinese Patients with Relapse\/Refractory Diffuse Large B Cell Lymphoma","volume":"10","author":"Liu","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1097\/HS9.0000000000000798","article-title":"Real-World Outcomes of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma Treated With Polatuzumab Vedotin-Based Therapy","volume":"6","author":"Argnani","year":"2022","journal-title":"Hemasphere"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Radhakrishnan, V.S., Pincha, R., Raina, V., Garg, J.K., Nag, A., Bhave, S.J., Achari, R., Dey, D., Arun, I., and Lateef, Z. (2022). Salvage Using Polatuzumab Vedotin Based Therapy in Relapsed Refractory Large B-Cell Lymphomas: Early Experience from a Real-World Middle-Income Setting Using Named-Patient Compassionate Access Program. Indian J. Hematol. Blood Transfus.","DOI":"10.1007\/s12288-022-01619-w"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/bloodadvances.2021005953","article-title":"Results of a United Kingdom Real-World Study of Polatuzumab Vedotin, Bendamustine, and Rituximab for Relapsed\/Refractory DLBCL","volume":"6","author":"Northend","year":"2022","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-16-0772","article-title":"Phase i Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with\/without Rituximab in Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"23","author":"Advani","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Levy, M.Y., Grudeva-Popova, Z., Trneny, M., Jurczak, W., Pylypenko, H., Jagadeesh, D., Andre, M., Nasta, S., Rechavi-Robinson, D., and Toffanin, S. (2021). Safety and Efficacy of CD37-Targeting Naratuximab Emtansine Plus Rituximab in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin\u2019s B-Cell Lymphomas\u2014A Phase 2 Study. Hematol. Oncol., 39.","DOI":"10.1002\/hon.156_2880"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2021-148607","article-title":"Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-Clinical Pharmacology and Mechanism of Action of SG3199, the Pyrrolobenzodiazepine (PBD) Dimer Warhead Component of Antibody-Drug Conjugate (ADC) Payload Tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific Antibody Based Therapeutics: Strengths and Challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and Molecular Correlates of Response to Glofitamab in Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"6","author":"Korfi","year":"2022","journal-title":"Blood Adv."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1182\/blood-2022-157732","article-title":"Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study","volume":"140","author":"Topp","year":"2022","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting t-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase i Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2022-157554","article-title":"Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment","volume":"140","author":"Hutchings","year":"2022","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to Watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Salvaris, R., Ong, J., and Gregory, G.P. (2021). Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050355"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1182\/blood-2022-157768","article-title":"Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly\/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"140","author":"Olszewski","year":"2022","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a Novel CD20\/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1182\/blood-2022-158245","article-title":"Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL)","volume":"140","author":"Phillips","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous Epcoritamab + R-Dhax\/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1\/2 Results","volume":"140","author":"Abrisqueta","year":"2022","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2022-158406","article-title":"Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy across Tumor Types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 Study of the Bispecific T-Cell Engager (Bite) Antibody Blinatumomab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, Phase 2 Study of Blinatumomab as Second Salvage Therapy in Adults with Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1080\/10428194.2020.1783442","article-title":"Durability of Complete Response after Blinatumomab Therapy for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"61","author":"Viardot","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-142464","article-title":"Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma","volume":"136","author":"Ghobadi","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2019-128255","article-title":"A Phase IB Study of Blinatumomab (Blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (Allo-BMT) Remission Maintenance","volume":"134","author":"Webster","year":"2019","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-136667","article-title":"Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group","volume":"136","author":"Guieze","year":"2020","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2021-144350","article-title":"Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab Tesirine in Patients with Relapsed or Refractory Lymphoma: A Phase 1, Open-Label, Multicentre, Dose-Escalation, Dose-Expansion Study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I\/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin with Rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bjh.14820","article-title":"Randomized, Phase 3 Trial of Inotuzumab Ozogamicin plus Rituximab versus Chemotherapy plus Rituximab for Relapsed\/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","volume":"182","author":"Dang","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_88","first-page":"2721","article-title":"Therapeutic Potential of an Anti-CD79b Antibody-Drug Conjugate, Anti-CD79b-vc-MMAE, for the Treatment of Non-Hodgkin Lymphoma","volume":"114","author":"Dornan","year":"2009","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1535-7163.MCT-12-1173","article-title":"DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma","volume":"12","author":"Li","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and Anti-CD79B Antibody Drug Conjugates Are Active in Different Molecular Diffuse Large B-Cell Lymphoma Subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Cheema, Y., Kiani, Y.S., Linton, K.J., and Jabeen, I. (2023). Identification and Empiric Evaluation of New Inhibitors of the Multidrug Transporter P-Glycoprotein (ABCB1). Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065298"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, Y., Fan, S., Xiao, D., Xie, F., Li, W., Zhong, W., and Zhou, X. (2019). Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy. Cancers, 11.","DOI":"10.3390\/cancers11070957"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-08-2250","article-title":"Antibody-Drug Conjugates for the Treatment of Non-Hodgkin\u2019s Lymphoma: Target and Linker-Drug Selection","volume":"69","author":"Poison","year":"2009","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"10532","DOI":"10.1039\/D2CC03052G","article-title":"A PH-Responsive Crosslinker Platform for Antibody-Drug Conjugate (ADC) Targeting Delivery","volume":"58","author":"Migliorini","year":"2022","journal-title":"Chem. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-Drug Conjugates for the Treatment of Lymphoma: Clinical Advances and Latest Progress","volume":"14","author":"Chu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"172738","DOI":"10.1016\/j.ejphar.2019.172738","article-title":"High Expression of NAMPT in Adult T-Cell Leukemia\/Lymphoma and Anti-Tumor Activity of a NAMPT Inhibitor","volume":"865","author":"Kozako","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_97","first-page":"100325","article-title":"Immunotherapy in Indolent Non-Hodgkin\u2019s Lymphoma","volume":"17","author":"Amhaz","year":"2022","journal-title":"Leuk. Res. Rep."},{"key":"ref_98","first-page":"10","article-title":"Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance","volume":"136","author":"Fiaschi","year":"2020","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2018889931","article-title":"PD-1\/PD-L1 Immune Checkpoint and P53 Loss Facilitate Tumor Progression in Activated B-Cell Diffuse Large B-Cell Lymphomas","volume":"133","author":"Pascual","year":"2019","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2017.10.022","article-title":"Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer","volume":"171","author":"Topper","year":"2017","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC Regulates the Antitumor Immune Response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting P53\u2013MDM2 Interaction by Small-Molecule Inhibitors: Learning from MDM2 Inhibitors in Clinical Trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T Cell Exhaustion\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1078-0432.CCR-21-3261","article-title":"Anti-CD79B Antibody\u2013Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study","volume":"28","author":"Herrera","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1182\/blood.V128.22.1841.1841","article-title":"ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity","volume":"128","author":"Ng","year":"2016","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1038\/s41467-020-19737-2","article-title":"Single Cell RNA Sequencing of Human Microglia Uncovers a Subset Associated with Alzheimer\u2019s Disease","volume":"11","author":"Olah","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1108297","DOI":"10.3389\/fneur.2023.1108297","article-title":"Novel Pathophysiological Insights into CAR-T Cell Associated Neurotoxicity","volume":"14","author":"Genoud","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"549842","DOI":"10.3389\/fimmu.2020.549842","article-title":"Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring","volume":"11","author":"Khoy","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib Mitigates Steroid-Refractory CRS during CAR T Therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"E273","DOI":"10.1002\/ajh.25591","article-title":"Rapid Relapse of Large B-Cell Lymphoma after CD19 Directed CAR-T-Cell Therapy Due to CD-19 Antigen Loss","volume":"94","author":"Bukhari","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical Lessons Learned from the First Leg of the CAR T Cell Journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_115","first-page":"e33169","article-title":"Treatments for Relapsed-Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody","volume":"14","author":"Messori","year":"2022","journal-title":"Cureus"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/PPO.0000000000000450","article-title":"Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma","volume":"26","author":"Roschewski","year":"2020","journal-title":"Cancer J."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Birtas Atesoglu, E., Gulbas, Z., Uzay, A., Ozcan, M., Ozkalemkas, F., Dal, M.S., Kalyon, H., Akay, O.M., Deveci, B., and Bekoz, H. (2023). Glofitamab in Relapsed\/Refractory Diffuse Large B-cell Lymphoma: Real-world Data. Hematol. Oncol.","DOI":"10.1002\/hon.3174"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/bloodadvances.2022007364","article-title":"Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies by Augmenting Tumor Cell Phagocytosis","volume":"6","author":"Vogiatzi","year":"2022","journal-title":"Blood Adv."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/14\/1858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:12:16Z","timestamp":1760127136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/14\/1858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":118,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cells12141858"],"URL":"https:\/\/doi.org\/10.3390\/cells12141858","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}